Transformative Advances in Neuroscience and Medical Applications with Graphene-Based Neurotechnology
A groundbreaking study recently published in Nature Nanotechnology has introduced an innovative graphene-based neurotechnology with the potential to revolutionize neuroscience and therapeutic applications. Spearheaded by the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in collaboration with the Universitat Autònoma de Barcelona (UAB) and other national and international partners, this research has paved the way for significant advancements in the field.
The key features of this graphene technology, developed under the European Graphene Flagship project, are high-precision neural interfaces and targeted nerve modulation. After years of research, ICN2 and the University of Manchester have successfully developed EGNITE (Engineered Graphene for Neural Interfaces), a flexible and high-resolution implantable neurotechnology. This novel technology integrates nanoporous graphene, which is regarding 100 times stronger than steel, into the fabrication processes used in the semiconductor industry. The result is graphene microelectrodes with low impedance and high charge injection, essential attributes for efficient neural interfaces.
Preclinical studies conducted by neuroscience and biomedical experts in collaboration with ICN2 have demonstrated the impressive functionality of EGNITE. These studies, using various models for the central and peripheral nervous systems, have shown that EGNITE can record high-fidelity neural signals with exceptional clarity and precision, while also providing highly targeted nerve modulation. This combination of capabilities represents a significant breakthrough in neuroelectronic therapeutics and addresses a critical gap in neurotechnology.
The collaboration involved in this research extends beyond ICN2 and UAB, encompassing leading national and international institutions such as the Institut de Microelectrònica de Barcelona – IMB-CNM (CSIC), the National Graphene Institute in Manchester (UK), the Grenoble Institut des Neurosciences – Université Grenoble Alpes (France), and the University of Barcelona. The successful integration of this technology into standard semiconductor fabrication processes was carried out at the Micro and Nanofabrication cleanroom of the IMB-CNM (CSIC), under the supervision of CIBER researcher Dr. Xavi Illa.
The commercialization of this technology has been facilitated through a patent and licensing agreement with INBRAIN Neuroelectronics, a Barcelona-based spin-off company founded by ICN2 and ICREA. INBRAIN Neuroelectronics, a partner in the Graphene Flagship project, is now leading the efforts to translate this innovative graphene technology into clinical applications and products. Under the guidance of CEO Carolina Aguilar, the company is preparing for first-in-human clinical trials.
The implications of this breakthrough neurotechnology are significant, not only for the field of neuroscience but also for various medical applications. With the potential to enhance neural recording and stimulation with unprecedented accuracy, this graphene-based neurotechnology might pave the way for groundbreaking advancements in the treatment of neurological disorders and the development of brain-computer interfaces.
Looking ahead, the future trends related to these themes hold great promise. The integration of graphene into neurotechnology opens up possibilities for further innovation and advancement in the field. As the industrial and innovation landscape on semiconductor engineering in Catalonia continues to evolve, with plans to establish state-of-the-art facilities for producing semiconductor technologies based on emerging materials, there’s an unprecedented opportunity to accelerate the translation of these research findings into clinical applications.
In conclusion, the introduction of graphene-based neurotechnology marks a transformative moment in the fields of neuroscience and medical applications. The collaborative efforts of ICN2, UAB, and other institutions have paved the way for high-precision neural interfaces and targeted nerve modulation. With the commercialization of this technology through INBRAIN Neuroelectronics, the potential for groundbreaking advancements in neuroelectronic therapeutics becomes a tangible reality. As the industry moves forward, it is imperative to embrace these emerging trends and utilize the full potential of graphene-based neurotechnology to improve the lives of countless individuals suffering from neurological disorders.
